In our study population, we found that serum levels of MIG and sCD25 were significantly higher in severe patients compared to non-severe ones, and MCP-1 and sTREM-1 aided in distinguishing between COVID-19 survivors and non-survivors, which is similar to the findings reported by Zhang et al. This evidence concerns the gene CXCL9 and COVID-19.